Novel anticancer function of inositol hexaphosphate: Inhibition of human rhabdomyosarcoma in vitro and in vivo

Anticancer Research

Volumn 18, Issue 3 A, 1998, Pages 1377-1384

  Vucenik, Ivana ^a   Kalebic, Thea ^b   Tantivejkul, Kwanchanit ^a   Shamsuddin, Abulkalam M ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Differentiation; Growth inhibition; IP6; Nude mice; RMS

Indexed keywords

PHYTIC ACID;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRAFT; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; CYTOPLASM; DOSE RESPONSE; HUMAN; HUMAN CELL; MESENCHYMOMA; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOFT TISSUE SARCOMA; TUMOR VOLUME; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MICE; MICE, NUDE; PHYTIC ACID; RHABDOMYOSARCOMA; TIME FACTORS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0031856814     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Shamsuddin AM: Inositol phosphates have novel anticancer function. J Nutr 125: 725S-732S, 1995.
2. 6: A novel anticancer agent. Life Sciences 61: 343-354, 1997.
3. Pappo AB, Shapiro DN, Crist WM and Maurer M: Biology and therapy of pediatric rhabdomyosarcoma. J Clin Oncol 13: 2123-2139, 1995.
4. Raney RB, Hays DM, Teffl M, et al. Rhabdomyosarcoma and the undifferentiated sarcomas. In: Principles and practice of pediatric oncology (Pizzo, PA and Poplack DG, eds). Philadelphia, PA, Lippincott, 1993, pp 769-794.
5. Aguanno S, Bousche M, Adamo S and Molinaro M: 12-O-Tetradecanoylphorbol-13-acetate-induced differentiation of human rhabdomyosarcoma cell line. Cancer Res 50: 3372-3382, 1990.
6. Minniti CP, Maggi M and Helman LJ: Suramin inhibits the growth of human rhabdomyosarcoma by interrupting the insulin-like growth factor II autocrine growth loop. Cancer Res 52: 1830-1835, 1992.
7. Kalebic T, Tsokos M and Helman LJ: In vivo treatment with antibody against 1GF-1 receptor suppresses growth of human rhabdomyosarcoma and down-regulates p34cdc2. Cancer Res 54: 5531-5534, 1994.
8. Kalebic T, Tsokos M and Helman LJ: Suppression of rhabdomyosarcoma growth by fumagillin analog TNP-470. Int J Cancer 68: 596-599, 1996.
9. Sakamoto K, Venkatraman G and Shamsuddin AM: Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). Carcinogenesis 14: 1815-1819, 1993.
10. Shamsuddin AM and Yang G: Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. Carcinogenesis 16: 1975-1979, 1995.
11. 6: Growth inhibition and differentiation of human mammary cancer cell lines in vitro. Anticancer Res 16: 3287-3292, 1996.
12. Vucenik I, Tomazic VJ, Fabian D and Shamsuddin AM: Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, a pilot study. Cancer Lett 65: 9-13, 1992.
13. Jariwalla RJ, Sabin R, Lawson S, Bloch DA, Prender M, Andrews V and Herman ZS: Effect of dietary phytic acid (phytate) on the incidence and growth rate of tumors promoted in Fisher rats by magnesium supplement. Nutr Res 8: 813-827, 1988.
14. Babich H, Borenfreund E and Stern A: Comparative cytotoxicities of selected minor dietary non-nutrients with chemopreventive properties. Cancer Lett 73: 127-133, 1993.
15. McAllister R, Melnyk J, Finklestein J, Adams EJr and Gardner M: Cultivation in vitro of cells derived from a human rhabdomyosarcoma. Cancer 24: 520-526, 1969.
16. Denizot F and Lang R: Rapid colorimetric assay for cell growth and survival: modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 89: 271-277, 1986.
17. Lollini PL, De Giovanni C, Del Re B, Landuzzi L, Nicoletti G and Prodi G: Myogenic differentiation of human rhabdomyosarcoma cells induced in vitro by antineoplastic drugs. Cancer Res 49: 3631-3636, 1989.
18. Crouch GD, Kalebic T, Tsokos M and Helman LJ: Ara-C treatment leads to differentiation and reverses the transformed phenotype in a human rhabdomyosarcoma cell line. Exper Cell Res 204: 210-216, 1993.
19. Melguizo C, Prados J, Marchai JA, Aranega AE, Alvarez L and Aranega A: Low concentrations of actinomycin D potentially cause therapeutic differentiation in human rhabdomyosarcoma cell line RD. Path Res Pract 192: 188-194, 1996.
20. Shamsuddin AM and Ullah A: Inositol hexaphosphate inhibits large intestinal cancer in F344 rats 5 months after induction by azoxymethane. Carcinogenesis 10: 625-626, 1989.
21. Vucenik I. Yang G and Shamsuddin AM: Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer. Carcinogenesis 16: 1055-1058, 1995.
22. Vucenik I, Tomazic VJ, Fabian D and Shamsuddin AM: Antitumor activity of phytic acid in murine transplanted and metastatic fibrosarcoma. Cancer Lett 65: 9-13, 1992.
23. 6): An antagonist of fibroblast growth factor receptor binding and activity. In Vitro Cell Dev Biol 30A: 783-789, 1994.
24. 6) and insulin-like growth factor II receptor binding sites in the rat brain. Neuroreport 5: 625-628, 1994.
25. Huang C, Ma W-Y, Hecht SS and Dong Z: Inositol hexaphosphate inhibits cell transformation and activator protein 1 activation by targeting phosphatidylinositol-3' kinase. Cancer Res 57: 2873-2878, 1997.
26. 31P NMR. Biochem Biophys Res Commun 264: 874-881, 1987.
27. Vaxman S: Meeting report: differentiation therapy. Cancer Res 50: 3453-3464, 1990.